ClinicalTrials.gg
CompletedNCT01483599X-PLOREUpdated Aug 2, 2017Results posted

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

A Phase 2 interventional study of CNTO 1959 (5 mg) and CNTO 1959 (15 mg) in Psoriasis, sponsored by Janssen Inc.. Completed at 40 sites in 5 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-08-02.

Sponsored by Janssen Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
293
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
8th of 29
293 · median 120
Started
2011
with 1 other
Phase 2
2 of 29
none open now
Registered
2nd of 29
by date
Lead sponsor
1 of 29
Janssen Inc.

Among the 29 studies testing guselkumab in Psoriasis, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is one of 2 in phase 2, and was the 2nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.

Read the detailed description

This is a multicenter, dose-ranging study of CNTO 1959 in patients with moderate to severe plaque psoriasis. Patients who satisfy all inclusion and exclusion criteria will be assigned by chance to one of 7 treatment groups: a placebo group (a placebo is a treatment identical in appearance to CNTO 1959 but does not contain active drug), 1 of 5 dose groups for CNTO 1959, or adalimumab. Patients assigned to adalimumab will be dosed according to the labeled dosing for psoriasis. At Week 16, patients initially assigned to placebo will begin receiving CNTO 1959. Patients initially assigned to CNTO 1959 will continue to receive the same assigned dose level of study agent from Week 16 through Week 40. Patients receiving adalimumab will continue the labeled dosing regimen. All patients will be reassessed for clinical response every 4 weeks from Week 4 through Week 40. Patients will continue dosing through Week 40, with a subsequent efficacy and safety follow-up visit at Week 52. Patient safety will be monitored throughout the study.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Moderate to Severe Plaque-Type Psoriasis
  • Psoriasis
  • Plaque-type psoriasis
  • CNTO 1959
  • adalimumab
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent
  • Must be a candidate for phototherapy or systemic treatment for psoriasis (either new to treatment or having had previous treatment)
  • Must be considered, in the opinion of the investigator, suitable candidates for adalimumab therapy
  • If a woman, she must be , or if premenopausal, she must be either surgically sterile, practicing a highly effective method of , or not heterosexually active during the study and for 5 months after receiving the last dose of study drug
  • If a man, he must agree to use a double-barrier method of birth control (or must have been surgically sterilized) and to not donate sperm during the study and for 5 months after receiving the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease
  • Has a to anti-TNF therapy
  • Has a history of chronic or recurrent infectious disease
  • Has a nonplaque form of psoriasis or has drug-induced psoriasis
  • Has been previously treated with adalimumab
  • Has received any therapeutic agent directly targeted to IL-12, IL-17, or IL-23, (including but not limited to ustekinumab, briakinumab [ABT-874], AIN457, and SCH900222) within 6 months of the first administration of study agent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
293 participants (actual)

Study arms

  • Experimental
    CNTO 1959 (5 mg)

    CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40

    Drug: CNTO 1959 (5 mg)

  • Experimental
    CNTO 1959 (15 mg)

    CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40

    Drug: CNTO 1959 (15 mg)

  • Experimental
    CNTO 1959 (50 mg)

    CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40

    Drug: CNTO 1959 (50 mg)

  • Experimental
    CNTO 1959 (100 mg)

    CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40

    Drug: CNTO 1959 (100 mg)

  • Experimental
    CNTO 1959 (200 mg)

    CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40

    Drug: CNTO 1959 (200 mg)

  • Active comparator
    Adalimumab (approved psoriasis dosing)

    Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)

    Drug: Adalimumab

  • Placebo comparator
    Placebo to CNTO 1959 (100 mg)

    Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40

    Drug: CNTO 1959 (100 mg) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 16

    PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.

    Time frame: Week 16

  2. Difference in Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) in CNTO1959 Groups Compared With Adalimumab Group at Week 16

    PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).

    Time frame: Week 16

  3. Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 40

    PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).

    Time frame: Week 40

  4. Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16

    The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

    Time frame: Baseline and Week 16

07

Results

Posted Aug 2, 2017

Participant flow

Controlled Period (CP) (up to Week 16)
Participant flow — Controlled Period (CP) (up to Week 16)
MilestonePlacebo (CP)CNTO1959 5 mg (CP)CNTO1959 15 mg (CP)CNTO1959 50 mg (CP)CNTO1959 100 mg (CP)CNTO1959 200 mg (CP)Adalimumab (CP)Placebo -> 100 mg CNTO1959 (After CP)CNTO1959 5 mg (After CP)CNTO1959 15 mg (After CP)CNTO1959 50 mg (After CP)CNTO1959 100 mg (After CP)CNTO1959 200 mg (After CP)Adalimumab (After CP)
Started424141424242430000000
Treated424141424241430000000
Completed393841394038390000000
Not completed33032440000000
Withdrew: Adverse event20011430000000
Withdrew: Lost to follow-up01010010000000
Withdrew: Lack of efficacy10000000000000
Withdrew: Other02011000000000
After Controlled Period(Week 16-Week 40)
Participant flow — After Controlled Period(Week 16-Week 40)
MilestonePlacebo (CP)CNTO1959 5 mg (CP)CNTO1959 15 mg (CP)CNTO1959 50 mg (CP)CNTO1959 100 mg (CP)CNTO1959 200 mg (CP)Adalimumab (CP)Placebo -> 100 mg CNTO1959 (After CP)CNTO1959 5 mg (After CP)CNTO1959 15 mg (After CP)CNTO1959 50 mg (After CP)CNTO1959 100 mg (After CP)CNTO1959 200 mg (After CP)Adalimumab (After CP)
Started000000039384139403839
Completed000000037293737393532
Not completed00000002942137
Withdrew: Death00000000100000
Withdrew: Adverse event00000001100011
Withdrew: Lost to follow-up00000000100101
Withdrew: Withdrawal by subject00000000102001
Withdrew: Lack of efficacy00000000500014
Withdrew: Other00000001040010

Outcome measures

PrimaryPercentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 16

PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 16
percentage of participantsPlaceboCNTO1959 5 mgCNTO1959 15 mgCNTO1959 50 mgCNTO1959 100 mgCNTO1959 200 mgAdalimumab
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 167.134.161.078.685.783.358.1
Statistical analysis
  • Placebo vs CNTO1959 5 mg · Cochran-Mantel-Haenszel chi-square test · p = 0.002
  • Placebo vs CNTO1959 15 mg · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
  • Placebo vs CNTO1959 50 mg · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
  • Placebo vs CNTO1959 100 mg · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
  • Placebo vs CNTO1959 200 mg · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
  • Placebo vs Adalimumab · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
SecondaryPercentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
percentage of participantsPlaceboCNTO1959 5 mgCNTO1959 15 mgCNTO1959 50 mgCNTO1959 100 mgCNTO1959 200 mgAdalimumab
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 164.843.975.681.078.681.069.8
Statistical analysis
  • Placebo vs CNTO1959 5 mg · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
  • Placebo vs CNTO1959 15 mg · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
  • Placebo vs CNTO1959 50 mg · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
  • Placebo vs CNTO1959 100 mg · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
  • Placebo vs CNTO1959 200 mg · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
  • Placebo vs Adalimumab · Cochran-Mantel-Haenszel chi-square test · p = < 0.001
SecondaryDifference in Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) in CNTO1959 Groups Compared With Adalimumab Group at Week 16

PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Difference in Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) in CNTO1959 Groups Compared With Adalimumab Group at Week 16
percentage of participantsCNTO1959 5 mgCNTO1959 15 mgCNTO1959 50 mgCNTO1959 100 mgCNTO1959 200 mgAdalimumab
Difference in Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) in CNTO1959 Groups Compared With Adalimumab Group at Week 1634.161.078.685.783.358.1
Statistical analysis
  • CNTO1959 5 mg vs Adalimumab · Difference in percentage: -24.0 · 95% CI -44.0 to -4.0
  • CNTO1959 15 mg vs Adalimumab · Difference in percentage: 2.8 · 95% CI -17.9 to 23.5
  • CNTO1959 50 mg vs Adalimumab · Difference in percentage: 20.4 · 95% CI 1.5 to 39.3
  • CNTO1959 100 mg vs Adalimumab · Difference in percentage: 27.7 · 95% CI 9.8 to 45.6
  • CNTO1959 200 mg vs Adalimumab · Difference in percentage: 25.4 · 95% CI 7.2 to 43.6
SecondaryPercentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 40

PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 40
percentage of participantsCNTO1959 5 mgCNTO1959 15 mgCNTO1959 50 mgCNTO1959 100 mgCNTO1959 200 mgAdalimumab
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 4035.359.571.176.981.148.6
Statistical analysis
  • CNTO1959 5 mg vs Adalimumab · Difference in percentage: -15.4 · 95% CI -37.7 to 6.9
  • CNTO1959 15 mg vs Adalimumab · Difference in percentage: 10.8 · 95% CI -10.7 to 32.4
  • CNTO1959 50 mg vs Adalimumab · Difference in percentage: 22.7 · 95% CI 1.8 to 43.6
  • CNTO1959 100 mg vs Adalimumab · Difference in percentage: 28.7 · 95% CI 8.5 to 49.0
  • CNTO1959 200 mg vs Adalimumab · Difference in percentage: 32.9 · 95% CI 13.0 to 52.8
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16

The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
units on a scalePlaceboCNTO1959 5 mgCNTO1959 15 mgCNTO1959 50 mgCNTO1959 100 mgCNTO1959 200 mgAdalimumab
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16-2.3 ± 6.80-6.2 ± 5.24-10.3 ± 5.49-11.1 ± 7.38-10.8 ± 7.34-11.4 ± 6.83-10.1 ± 9.00
Statistical analysis
  • Placebo vs CNTO1959 5 mg · ANOVA on the van Der Waerden score · p = 0.008
  • Placebo vs CNTO1959 15 mg · ANOVA on the van Der Waerden score · p = < 0.001
  • Placebo vs CNTO1959 50 mg · ANOVA on the van Der Waerden score · p = < 0.001
  • Placebo vs CNTO1959 100 mg · ANOVA on the van Der Waerden score · p = < 0.001
  • Placebo vs CNTO1959 200 mg · ANOVA on the van Der Waerden score · p = < 0.001
  • Placebo vs Adalimumab · ANOVA on the van Der Waerden score · p = < 0.001

Adverse events

Collected over Baseline (Week 0) up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (CP)—1/42 (2.4%)13/42 (31%)
CNTO1959 5 mg (CP)—0/41 (0%)15/41 (36.6%)
CNTO1959 15 mg (CP)—0/41 (0%)10/41 (24.4%)
CNTO1959 50 mg (CP)—3/42 (7.1%)10/42 (23.8%)
CNTO1959 100 mg (CP)—0/42 (0%)7/42 (16.7%)
CNTO1959 200 mg (CP)—0/41 (0%)8/41 (19.5%)
Adalimumab (CP)—1/43 (2.3%)10/43 (23.3%)
Placebo -> 100 mg CNTO1959 (After CP)—0/39 (0%)16/39 (41%)
CNTO1959 5 mg (After CP)—2/38 (5.3%)12/38 (31.6%)
CNTO1959 15 mg (After CP)—0/41 (0%)4/41 (9.8%)
CNTO1959 50 mg (After CP)—0/39 (0%)11/39 (28.2%)
CNTO1959 100 mg (After CP)—2/40 (5%)16/40 (40%)
CNTO1959 200 mg (After CP)—0/38 (0%)12/38 (31.6%)
Adalimumab (After CP)—1/38 (2.6%)13/38 (34.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlacebo (CP)CNTO1959 5 mg (CP)CNTO1959 15 mg (CP)CNTO1959 50 mg (CP)CNTO1959 100 mg (CP)CNTO1959 200 mg (CP)Adalimumab (CP)Placebo -> 100 mg CNTO1959 (After CP)CNTO1959 5 mg (After CP)CNTO1959 15 mg (After CP)CNTO1959 50 mg (After CP)CNTO1959 100 mg (After CP)CNTO1959 200 mg (After CP)Adalimumab (After CP)
Myocardial InfarctionCardiac disorders0/420/410/410/420/420/410/430/391/380/410/391/400/380/38
Oesophagitis HaemorrhagicGastrointestinal disorders0/420/410/410/420/420/410/430/390/380/410/390/400/381/38
PneumoniaInfections and infestations0/420/410/410/420/420/410/430/390/380/410/390/400/381/38
HyperglycaemiaMetabolism and nutrition disorders0/420/410/410/420/420/410/430/390/380/410/390/400/381/38
OsteoarthritisMusculoskeletal and connective tissue disorders0/420/410/410/420/420/410/430/391/380/410/390/400/380/38
Cerebrovascular AccidentNervous system disorders0/420/410/410/420/420/410/430/390/380/410/391/400/380/38
Umbilical HerniaGastrointestinal disorders0/420/410/411/420/420/410/430/390/380/410/390/400/380/38
AppendicitisInfections and infestations0/420/410/411/420/420/410/430/390/380/410/390/400/380/38
Lung AbscessInfections and infestations0/420/410/411/420/420/410/430/390/380/410/390/400/380/38
Uterine ProlapseReproductive system and breast disorders1/420/410/410/420/420/410/430/390/380/410/390/400/380/38
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlacebo (CP)CNTO1959 5 mg (CP)CNTO1959 15 mg (CP)CNTO1959 50 mg (CP)CNTO1959 100 mg (CP)CNTO1959 200 mg (CP)Adalimumab (CP)Placebo -> 100 mg CNTO1959 (After CP)CNTO1959 5 mg (After CP)CNTO1959 15 mg (After CP)CNTO1959 50 mg (After CP)CNTO1959 100 mg (After CP)CNTO1959 200 mg (After CP)Adalimumab (After CP)
NasopharyngitisInfections and infestations1/426/414/411/421/422/412/434/396/381/417/394/405/386/38
Injection Site ErythemaGeneral disorders1/420/410/410/421/421/415/430/390/380/410/390/400/382/38
Upper Respiratory Tract InfectionInfections and infestations1/423/410/411/420/423/412/434/394/381/410/393/402/383/38
HeadacheNervous system disorders1/423/414/411/422/420/410/431/391/380/411/392/401/380/38
PsoriasisSkin and subcutaneous tissue disorders4/421/410/410/420/420/410/430/390/380/410/390/400/381/38
ArthralgiaMusculoskeletal and connective tissue disorders1/421/410/411/421/421/412/433/392/380/410/391/401/381/38
Back PainMusculoskeletal and connective tissue disorders0/423/411/410/422/420/410/430/390/381/411/392/401/380/38
FatigueGeneral disorders3/421/411/412/420/420/410/430/390/380/410/390/401/380/38
HypertensionVascular disorders1/421/410/413/421/421/410/431/390/380/411/392/401/381/38
Influenza Like IllnessGeneral disorders0/420/411/410/420/420/410/430/390/380/410/390/400/382/38

Baseline characteristics

Population analyzed included all participants who were randomized.

Age, Categorical
Age, Categorical(Participants)PlaceboCNTO1959 5 mgCNTO1959 15 mgCNTO1959 50 mgCNTO1959 100 mgCNTO1959 200 mgAdalimumabTotal
<=18 years01000001
Between 18 and 65 years41393941364035271
>=65 years112162821
Age, Continuous
Age, Continuous(years)PlaceboCNTO1959 5 mgCNTO1959 15 mgCNTO1959 50 mgCNTO1959 100 mgCNTO1959 200 mgAdalimumabTotal
Mean45 ± 11.9745.2 ± 13.9243.8 ± 13.542.6 ± 12.1445.3 ± 13.7245.1 ± 10.9647.5 ± 14.9144.9 ± 13.02
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCNTO1959 5 mgCNTO1959 15 mgCNTO1959 50 mgCNTO1959 100 mgCNTO1959 200 mgAdalimumabTotal
Female1413131210111386
Male28282830323130207
Region of Enrollment
Region of Enrollment(participants)PlaceboCNTO1959 5 mgCNTO1959 15 mgCNTO1959 50 mgCNTO1959 100 mgCNTO1959 200 mgAdalimumabTotal
Germany224543323
Belgium21001105
Poland7871078855
Canada1311111112141183
United States18191916181621127
08

Study locations

40 sites
  • Birmingham, Alabama, United States
  • Bakersfield, California, United States
  • Los Angeles, California, United States
  • Santa Monica, California, United States
  • Ocala, Florida, United States
  • Alpharetta, Georgia, United States
  • Arlington Heights, Illinois, United States
  • Skokie, Illinois, United States
  • Indianapolis, Indiana, United States
  • Louisville, Kentucky, United States
  • Andover, Massachusetts, United States
  • Boston, Massachusetts, United States
  • Saint Louis, Missouri, United States
  • Albuquerque, New Mexico, United States
  • New York, New York, United States
  • Portland, Oregon, United States
  • Pittsburgh, Pennsylvania, United States
  • Houston, Texas, United States
  • Brussel, Belgium
  • Gent, Belgium
  • Liege, Belgium
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Moncton, New Brunswick, Canada
  • Halifax, Nova Scotia, Canada
  • Hamilton, Ontario, Canada
  • London, Ontario, Canada
  • Oakville, Ontario, Canada
  • Toronto, Ontario, Canada
  • Waterloo, Ontario, Canada
  • Montreal, Quebec, Canada
  • Quebec, Canada
  • Hamburg, Germany
  • Mahlow, Germany
  • Munster, Germany
  • Schwerin, Germany
  • Gdansk, Poland
  • Konskie N/A, Poland
  • Lodz, Poland
  • Wroclaw, Poland
09

References and documents

Publications

  • Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015 Jul 9;373(2):136-44. doi: 10.1056/NEJMoa1501646. PubMed 26154787 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Nov 2012, 12 months.

Results were first posted in Aug 2017, 4 years 8 months after primary completion. A results delay was requested in Oct 2013.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 12 months is close to that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2011
First posted
Dec 1, 2011
StartActual
Nov 10, 2011
Primary completionActual
Nov 27, 2012
CompletionActual
Aug 5, 2013
Results delay requested
Oct 16, 2013
Results first posted
Aug 2, 2017
Last update
Aug 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01483599
Lead sponsor
Janssen Inc.
Responsible party
Sponsor
First posted
Dec 1, 2011
Start date
Nov 10, 2011
Primary completion
Nov 27, 2012
Completion
Aug 5, 2013
Results posted
Aug 2, 2017
Last update
Aug 2, 2017

Study contacts

Janssen Inc. Clinical Trial
study director · Janssen Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion